menu
    • menu
    [{"orgOrder":0,"company":"Imperial College London","sponsor":"Trevena","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"TRV027","moa":"AT1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Trevena","highestDevelopmentStatusID":"6","companyTruncated":"Imperial College London \/ Trevena"},{"orgOrder":0,"company":"NeRRe Therapeutics","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Orvepitant Maleate","moa":"NK-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"NeRRe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeRRe Therapeutics \/ Columbus Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"NeRRe Therapeutics \/ Columbus Venture Partners"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"ETD002","moa":"Anoctamin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterprise Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Enterprise Therapeutics \/ F. Hoffmann-La Roche"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NeRRe Therapeutics

                            United Kingdom arrow
                            Indo Livestock Expo
                            Not Confirmed

                            NeRRe Therapeutics

                            United Kingdom arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orvepitant Maleate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Columbus Venture Partners

                            Deal Size : $27.8 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            NeRRe Therapeutics Raises £20 Million in a Series B2 Financing Round

                            Details : New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis (IPF). The chronic cough can markedly reduce quality of life, is often refractory to medical therapy and there are no approved t...

                            Product Name : GW823296X

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 07, 2021

                            Lead Product(s) : Orvepitant Maleate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Columbus Venture Partners

                            Deal Size : $27.8 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Enterprise Therapeutics

                            United Kingdom arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Enterprise Therapeutics

                            United Kingdom arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETD002

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Enterprise Therapeutics’ TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory ...

                            Details : Enterprise Therapeutics' TMEM16A portfolio includes ETD002, first of its compounds to hit clinical stage. In pre-clinical models the compound has been found to enhances the activity of TMEM16A.

                            Product Name : ETD002

                            Product Type : Other Small Molecule

                            Upfront Cash : $96.8 milion

                            July 10, 2020

                            Lead Product(s) : ETD002

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Imperial College London

                            United Kingdom arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Imperial College London

                            United Kingdom arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRV027

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Trevena

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients

                            Details : Collaboration to evaluate the potential of TRV027, a novel AT1 receptor selective agonist, to treat acute lung injury contributing to acute respiratory distress syndrome (ARDS) in COVID-19 patients.

                            Product Name : TRV027

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            February 06, 2020

                            Lead Product(s) : TRV027

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Trevena

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth